Drug Profile
N-methyl amisulpride - LB pharmaceuticals
Alternative Names: LB 102; LB 102 LAI; LB-102 - LB PharmaceuticalsLatest Information Update: 26 Dec 2023
Price :
$50
*
At a glance
- Originator LB Pharmaceuticals
- Class Antidepressants; Antiemetics; Antipsychotics; Benzamides; Pyrrolidines; Small molecules; Sulfones
- Mechanism of Action Dopamine D2 receptor antagonists; Dopamine D3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Schizophrenia
Most Recent Events
- 04 Dec 2023 LB Pharmaceuticals initiates enrolment in a phase II trial for Schizophrenia in USA (PO, Capsule) (NCT06179108)
- 13 Jul 2023 Phase-I clinical trials in Schizophrenia in USA (Parenteral), prior to July 2023 (LB Pharmaceuticals pipeline, July 2023)
- 13 Jul 2023 Phase-II clinical trials in Schizophrenia in USA (PO), prior to July 2023 (LB Pharmaceuticals pipeline, July 2023)